Working… Menu

Phase 1/2 Study of X-396, an Oral ALK Inhibitor, in Patients With ALK-positive Non-Small Cell Lung Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT01625234
Recruitment Status : Recruiting
First Posted : June 21, 2012
Last Update Posted : July 16, 2018
Information provided by (Responsible Party):
Xcovery Holding Company, LLC